IART · Integra Lifesciences Holdings Corp · Financials

$11.89 -0.44 (-3.56%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$958.55M

77.77M

Volume · Oct 23 119.11K Avg daily vol (3M) 956.25K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$1.64B +1.5%

FY2025

Net Income

-$516.47M -7337.7%

FY2025

Gross Margin

50.86% -3.9pp

FY2025

Operating Margin

-30.17% -31.9pp

FY2025

Diluted EPS

-$6.74 -7388.9%

FY2025

Operating Cash Flow

$50.38M -61.1%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+1.6%	+3.6%	—	$1.63B – $1.65B	$1.65B	$1.64B^G	$1.61B^G	$1.54B^G	$1.56B^G	$1.54B^G	$1.37B	$1.52B	$1.47B	$1.19B	$992.08M	—	—	—	—	—	—	—	—
Cost of Revenue	+11.0%	+9.1%	+9.4%	—	$783.08M	$803.63M	$728.47M	$656.84M	$587.36M	$597.81M	$520.83M	$564.68M	$571.5M	$435.51M	$349.09M	$326.54M	$302.95M	$279.55M	$314.43M	$299.15M	$268.19M	$244.92M	$252.83M
Gross Profit	-5.0%	-0.5%	+4.1%	—	$864.58M	$831.62M^d	$882.06M^d	$884.74M^d	$970.31M^d	$944.64M^d	$851.03M	$952.88M	$900.95M	$752.73M	$642.99M	$556.19M	$493.77M	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	50.86%^d	54.77%^d	57.39%^d	62.29%^d	61.24%^d	62.03%	62.79%	61.19%	63.35%	64.81%	—	—	—	—	—	—	—	—
Research & Development	-0.7%	+5.0%	+6.9%	—	$95M	$98.97M	$115.38M	$104.19M	$101.19M	$93.05M	$77.38M	$79.57M	$78.04M	$63.46M	$58.16M	$50.9M	$43.56M	$42.62M	$51.01M	$51.45M	$48.11M	$44.28M	$60.5M
Selling, General & Administrative	+4.3%	+3.3%	+5.3%	—	$688.98M	$699.7M	$716.98M	$656.64M	$616.32M	$637.45M	$594.53M	$687.6M	$690.75M	$624.1M	$455.63M	$415.76M	$375.55M	$332.19M	$373.11M	$358.13M	$305.06M	$281.1M	$281M
Amortization of Intangibles	+2.5%	-11.6%	+4.2%	—	$15.04M	$14.95M	$21.29M	$12.38M	$13.88M	$16.91M	$27.76M	$27.03M	$21.16M	$20.37M	$13.86M	$9.95M	$6.81M	$7.1M	$18.54M	$16.43M	$12.02M	$14.36M	$12.88M
Depreciation & Amortization	—	—	—	—	—	—	—	—	—	—	—	$109.46M	$110.73M	$88.95M	$72.67M	$58.86M	$46.43M	$31.01M	$52.61M	$50.17M	$39.17M	$39.69M	$30.72M
Total Costs & Expenses	+17.3%	+11.8%	+10.2%	—	$1.58B	$2.13B	$1.58B	$1.43B	$1.32B	$1.35B	$1.22B	$1.42B	$1.36B	$1.14B	$876.74M	$803.15M	$728.86M	$661.46M	$757.09M	$725.17M	$633.37M	$584.66M	$607.19M
Operating Income	—	—	—	—	$65.56M	-$493.37M	$28.41M	$111.53M	$238.92M	$197.23M	$151.37M	$93.76M	$111M	$44.8M	$115.34M	$79.59M	$67.86M	$35.37M	$73.78M	$54.91M	$98.69M	$97.82M	$47.41M
Operating Margin	—	—	—	—	—	-30.17%	1.76%	7.23%	15.34%	12.79%	11.03%	6.18%	7.54%	3.77%	11.63%	—	—	—	—	—	—	—	—
EBITDA	—	—	—	—	—	—	—	—	—	—	—	$203.22M	$221.73M	$133.75M	$188.01M	$138.45M	$114.29M	$66.39M	$126.39M	$105.08M	$137.87M	$137.51M	$78.13M
Interest Expense	+20.3%	+3.8%	+13.9%	—	$91.86M	$86.26M	$70.63M	$51.38M	$49.59M	$50.4M	$71.58M	$53.96M	$64.68M	$35.02M	$25.8M	$23.53M	$21.97M	$19.73M	$22.24M	$27.64M	$18.36M	$23.23M	$30.09M
Interest Income	+15.7%	+14.7%	+90.1%	—	$17.72M	$18.47M	$20.04M	$17.2M	$11.92M	$6.74M	$9.3M	$10.78M	$2.8M	$255K	$24K	$30K	$168K	$4.93M	$1.21M	$465K	$225K	$631K	$2.11M
Other Non-Operating Income	—	—	—	—	$8.41M	-$2.35M	$3.94M	$3.72M	$12.01M	$19.31M	$4.43M	$9.52M	$8.29M	$1.35M	$845K	$4.59M	-$492K	-$1.8M	-$721K	$757K	$1.55M	-$2.08M	-$905K
Pretax Income	—	—	—	—	-$179K	-$563.5M	-$18.24M	$81.07M	$213.89M	$214.68M	$93.52M	$60.1M	$57.4M	$11.39M	$90.41M	$60.67M	$45.57M	$18.79M	$52.03M	$28.49M	$82.11M	$73.15M	$18.54M
Income Tax	—	—	—	—	$7.06M	-$47.03M	-$11.29M	$13.33M	$33.34M	$45.6M	-$40.37M	$9.9M	-$3.4M	-$53.36M	$15.84M	$53.82M	$9.27M	-$3.24M	$10.83M	$505K	$16.45M	$22.2M	-$9.19M
Net Income	—	—	—	—	-$7.24M	-$516.47M	-$6.94M	$67.74M	$180.55M	$169.08M	$133.89M	$50.2M	$60.8M	$64.74M	$74.56M	-$3.52M	$34M	-$21.07M	$41.2M	$27.99M	$65.67M	$50.96M	$27.73M
Net Margin	—	—	—	—	—	-31.58%	-0.43%	4.39%	11.59%	10.96%	9.76%	3.31%	4.13%	5.45%	7.52%	—	—	—	—	—	—	—	—
Comprehensive Income	—	—	—	—	-$16.53M	-$518.98M	-$19.41M	$42.37M	$235.97M	$197.98M	$136.24M	$19.24M	$39.17M	$98.09M	$65.31M	-$27.93M	$9.59M	-$15.34M	$45.5M	$20.69M	$54.97M	$54.51M	$14.24M
EPS (Basic) USD/shares	—	—	—	—	-$0.10	-$6.74	-$0.09	$0.85	$2.18	$2.00	$1.58	$0.59	$0.73	$0.84	$1.00	-$0.05	$0.52	-$0.74	$1.46	$0.97	$2.21	$1.75	$0.98
EPS (Diluted) USD/shares	—	—	—	$2.30 – $2.40*	-$0.10	-$6.74^G	-$0.09^G	$0.84^G	$2.16^G	$1.98^G	$1.57	$0.58	$0.72	$0.82	$0.94	-$0.05	$0.52	-$0.74	$1.44	$0.95	$2.17	$1.74	$0.96
Shares Outstanding (Basic Avg) shares	-2.6%	-2.0%	+1.1%	—	—	76.67M	77.01M	80.09M	83M	84.7M	84.65M	85.64M	82.86M	76.9M	74.39M	68.99M	64.86M	28.42M	28.23M	28.95M	29.55M	29.04M	27.78M
Shares Outstanding (Diluted Avg) shares	-2.8%	-2.1%	+0.7%	—	—	76.67M	77.01M	80.34M	83.52M	85.49M	85.23M	86.49M	84M	79.12M	79.19M	71.35M	65.92M	28.8M	28.52M	29.5M	30.15M	29.29M	28.38M

^d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $667.43M in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Long-term debt, including current maturities	2026-06-30	USD 707,187,000	10-Q filed 2026-07-29
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of secured debt USD 43,594,000 Noncurrent secured debt USD 1,736,105,000
Operating lease liabilities	2026-06-30	USD 176,580,000	10-Q filed 2026-07-29
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 13,920,000 Noncurrent operating lease liabilities USD 162,660,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

0.84×

Peer median 2.94×

EV/EBIT

21.23×

Peer median 24.79×

P/E (TTM)

—

Peer median 27.06×

Peer medians compare against the 63 similar-size Medical Devices companies (of 156 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Codman Specialty Surgical	$1,200,511,000	$1,143,636,000	$1,058,993,000	$1,019,564,000	$1,025,232,000	$894,831,000	$996,206,000	$963,929,000
Tissue Technologies	$434,734,000	$466,891,000	$482,580,000	$538,102,000	$517,216,000	$477,037,000	$521,351,000	$508,512,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$1,204,745,000	$1,192,675,000	$1,100,730,000	$1,126,810,000	$1,089,526,000	$971,975,000	$1,077,379,000	$1,045,887,000
Asia Pacific	$189,251,000	$176,614,000	$193,096,000	$176,477,000	$182,034,000	$157,174,000	$157,391,000	$144,253,000
Europe	$162,666,000	$158,496,000	$165,221,000	$170,903,000	$191,327,000	$172,689,000	$197,468,000	$201,354,000
Rest of the World	$78,583,000	$82,742,000	$82,526,000	$83,476,000	$79,561,000	$70,030,000	$85,319,000	$80,947,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Neurosurgery	$827,667,000	$803,816,000	$818,101,000	$794,017,000	$802,959,000	$716,339,000	$767,793,000	$740,268,000
Regenerative Skin and Wound	$323,488,000	$350,565,000	$373,986,000	$406,689,000	$392,463,000	$586,076,000	$645,478,000	$311,565,000
Instruments	$206,472,000	$204,177,000	$203,617,000	$192,679,000	$222,273,000	$178,492,000	$228,413,000	$223,661,000
ENT	$166,372,000	$135,643,000	$37,275,000	$32,868,000	—	—	—	—
Private Label	$111,246,000	$116,326,000	$108,594,000	$131,413,000	$124,753,000	$211,366,000	$217,060,000	$106,359,000
Extremity Orthopedics	—	—	—	—	—	$156,632,000	$180,164,000	$90,588,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Codman Specialty Surgical	$120,877,000	$504,074,000	$450,530,000	$417,873,000	$439,471,000	$356,657,000	$395,019,000	$363,336,000
Tissue Technologies	-$31,072,000	$139,169,000	$134,048,000	$233,802,000	$228,199,000	$159,630,000	$144,638,000	$149,510,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Codman Specialty Surgical	10.1%	44.1%	42.5%	41%	42.9%	39.9%	39.7%	37.7%
Tissue Technologies	-7.1%	29.8%	27.8%	43.4%	44.1%	33.5%	27.7%	29.4%

Key facts CIK 917520 CUSIP 457985208 13F (30d) 26 filings 26 filers Visit website Investor relations